
Opinion|Videos|May 16, 2025
Current Treatments Options for Patients With CHE
Author(s)Raj Chovatiya, MD, PhD
An expert discusses how chronic hand eczema (CHE) treatment follows a stepwise approach from general care and barrier protection to topical therapies (corticosteroids and calcineurin inhibitors) and systemic options (alitretinoin, immunosuppressives, and newer biologics for atopic dermatitis).
Advertisement
Video content above is prompted by the following:
CHE Treatment Approaches
Key Themes:
- Treatment hierarchy: Baseline care (barrier protection, moisturization, and trigger avoidance), topical therapies, and systemic options.
- Topical treatments: Corticosteroids and calcineurin inhibitors show efficacy but have limitations for long-term use.
- Systemic options: Traditional immunosuppressants carry significant safety concerns, while newer targeted therapies for atopic dermatitis have been repurposed for CHE.
Notable Insights:
Dr Chovatiya discussed complications of long-term topical steroid use, including "skin thinning, loss of subcutaneous fat, potential systemic absorption, and even permanent depigmentation," emphasizing the need for better treatment options.
Advertisement
Related to this article

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.

A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.

Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.

Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.

Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Advertisement
Advertisement
Trending on HCPLive
1
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
2
Remibrutinib Receives FDA Approval for Symptomatic Dermographism
3
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5

